证券代码：002007 证券简称：华兰生物 公告编号：2025-028 华兰生物工程股份有限公司 第九届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华兰生物工程股份有限公司（以下简称"公司"）第九届董事会第一次会议于 2025 年 6 月 27 日以电话或电子邮件方式发出通知，于 2025 年 7 月 8 日下午在公司 办公室三楼以通讯表决的方式召开。 会议由公司董事长安康先生主持。会议应到董事 9 名，实到董事 9 名。会议符 合《公司法》和《公司章程》的规定。 二、董事会会议审议情况 经与会董事认真审议，形成如下决议： 1、审议通过了《关于选举董事长的议案》 选举安康先生为公司董事长。 表决结果：9票赞成，0票反对，0票弃权。 2、审议通过了《关于选举董事会专门委员会的议案》 董事会选举出的各专门委员会成员如下： 战略委员会由安康先生、范蓓女士、苏志国先生组成，其中安康先生担任召集 人。 薪酬与考核委员会由苏志国先生、刘万丽女士、安文珏女士组成，其中苏志国 先生担任召集人。 提名委员会由苏志国先生、王云 ...

Group 1 - The core point of the announcement is the capital increase of 50 million RMB for Hualan Gene Engineering Co., Ltd., a subsidiary of the company, to address its funding needs for ongoing clinical trials and operations [1][4][5] - The company will contribute 20 million RMB, maintaining its 40% ownership stake, while the actual controller, Mr. An Kang, will contribute 30 million RMB, keeping his 60% stake [1][2] - The capital increase will consist of 10 million RMB for registered capital and 40 million RMB for capital reserves, with the total assets of the gene company reported at approximately 1.53 billion RMB and liabilities at approximately 1.54 billion RMB as of December 31, 2024 [2][3] Group 2 - The gene company has been involved in the research and development of innovative drugs and biosimilars, with 10 products having received clinical trial approvals, including Bevacizumab, which received its drug registration certificate on November 21, 2024 [3] - The independent directors have reviewed and approved the capital increase proposal, affirming that it aligns with the interests of all shareholders and complies with relevant laws and regulations [5]

证券代码：002007 证券简称：华兰生物 公告编号：2025-030 华兰生物工程股份有限公司 华兰基因工程有限公司（以下简称"基因公司"）为本公司参股公司,目前注册 资本 20,000 万元人民币，其中本公司出资 8,000 万元，占注册资本的 40％；本公 司实际控制人安康先生出资 12,000 万元，占注册资本的 60％。根据生产经营需要， 基因公司拟增资 50,000 万元，其中 10,000 万元用于增加注册资本，40,000 万元用 于增加资本公积，为此原有股东按照原出资比例对基因公司进行增资，其中，本公 司拟按照 40%的比例以货币增资人民币 20,000 万元，认购基因公司新增的 4,000 万 元注册资本；安康先生按照 60％的比例以货币增资人民币 30,000 万元，认购基因 公司新增的 6,000 万元注册资本。增资完成后，本公司和安康先生的出资比例不变。 2、关联关系 基因公司为本公司与公司实际控制人安康先生共同投资，根据《深圳证券交易 所上市规则》的规定，本次交易构成关联交易。 3、关联交易的审议情况 关于对参股公司华兰基因工程有限公司增资暨关联交易的公告 本公司及董事会全体成员保 ...

证券代码：002007 证券简称：华兰生物 公告编号：2025-027 华兰生物工程股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 1、本次股东大会的召开时间： 现场会议召开时间为：2025年7月8日下午14:30 网络投票时间：2025年7月8日。其中通过深圳证券交易所交易系统进行网络投 票的具体时间为2025年7月8日上午9:15—9:25,9:30—11:30和下午13:00—15:00； 通过深圳证券交易所互联网投票的具体时间为2025年7月8日09:15至15:00期间的任 意时间。 2、会议召开地点：公司办公楼会议室 5、现场会议主持人：董事长安康先生 6、本次股东大会的会议召集、召开程序符合有关法律、法规、规范性文件及《公 司章程》的有关规定。 7、会议出席情况： （1）出席会议总体情况 出席本次股东大会现场会议和网络投票的股东及股东代理人共834人，代表股份 901, ...

安徽承义律师事务所 关于 华兰生物工程股份有限公司 召开 2025 年第一次临时股东大会的 法律意见书 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Website）: www.chengyi-law.com 电子信箱（E-mail）：chengyilawyer@163.com 安徽承义律师事务所 关于华兰生物工程股份有限公司 召开 2025 年第一次临时股东大会的法律意见书 （2025）承义法字第 00169 号 致：华兰生物工程股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 会规则》等法律法规和其他规范性文件的要求，安徽承义律师事务所接受华兰生 物工程股份有限公司（以下简称"公司"）的委托，指派鲍金桥、万晓宇律师（以 下简称"本律师"）就公司召开 2025 年第一次临时股东大会（以下简称"本次股东 大会"）出具法律意见书。 一、本次股东大会召集人资格和召集、召开的程序 经核查，本次股东大会是由公司第八届董事会召集， ...

Core Viewpoint - Hualan Biological's influenza vaccine has been removed from the World Health Organization's prequalification list, but the company asserts that this will not impact its overseas sales or overall performance [1]. Company Summary - Hualan Biological's influenza vaccine was first prequalified by the WHO in 2015, making it the first domestic influenza vaccine to receive this certification [4]. - The company plans to withdraw its three-valent influenza vaccine from the WHO prequalification list due to the age of its production facility, which has been in operation for 18 years [1]. - Hualan Biological's vaccine production capacity is robust, with the new production facilities (3/4/5/6) capable of producing 100 million doses of influenza vaccine annually [1]. Financial Performance - In 2024, Hualan Biological reported total revenue of 4.379 billion yuan, a year-on-year decrease of 18.02% [4]. - Vaccine products contributed 1.117 billion yuan to the total revenue, accounting for 25.51%, while blood products contributed 3.245 billion yuan, making up 74.12% of total revenue [4]. - The company's overseas business contributed only 1.727 million yuan, representing 0.04% of total revenue, indicating a strong focus on domestic operations [7]. Market Dynamics - The domestic influenza vaccine market is experiencing a price war, with significant price reductions initiated by major players, including Hualan Biological [10]. - Hualan's influenza vaccine prices have been reduced by approximately 30%, with specific products now priced at 88 yuan per dose for the four-valent influenza vaccine [10]. - The low vaccination rate in China, currently around 3%, is a significant barrier to market growth, with industry experts suggesting that lower prices could enhance vaccination uptake [10].

Core Viewpoint - The Chinese blood products industry is undergoing significant consolidation, with major players engaging in aggressive mergers and acquisitions to capture plasma resources, leading to the emergence of potential super giants in the sector [1][5]. Industry Landscape - The blood products industry in China is characterized by a "four-way" competitive landscape, dominated by four major groups: China National Pharmaceutical Group (Sinopharm), Haier Group, China Resources, and Hualan Biological Engineering [2][4]. - The industry has transitioned into a stock competition era since 2001, with new entrants needing to acquire existing licensed companies due to a moratorium on new licenses [2][3]. Mergers and Acquisitions - Significant acquisitions include China Resources' acquisition of Boya Biological for 4.8 billion yuan, Haier's 12.5 billion yuan acquisition of Shanghai Laishi, and Sinopharm's 4.5 billion yuan acquisition of Pilin Biological [1][2]. - The consolidation trend has led to a sharp increase in market concentration, with the top five companies' market share rising from under 50% in 2019 to over 70% by 2024 [4]. Plasma Collection and Utilization - Sinopharm's network includes 154 plasma collection stations, accounting for nearly 40% of the national total, with a collection volume of over 4,000 tons by mid-2025 [3]. - The cost structure of blood products heavily relies on raw plasma, which constitutes over 60% of total costs, making scale efficiency crucial for profitability [5][6]. Market Demand and Supply Gap - The domestic blood products market surpassed 60 billion yuan in 2023, with a demand gap of 4,000 tons, highlighting the need for leading companies to enhance their supply capabilities through technological upgrades [5][6]. - China's per capita consumption of blood products is significantly lower than that of developed countries, indicating a structural supply-demand imbalance [7][8]. Technological Advancements - Companies are shifting from a resource-driven model to a dual strategy of resource acquisition and research and development to overcome technological barriers and meet high-value product demands [9][10]. - Sinopharm and Hualan Biological are focusing on developing high-purity albumin and advanced coagulation factors, with significant investments in R&D to support these initiatives [10][11]. Future Outlook - The ongoing consolidation and technological advancements suggest that the Chinese blood products industry is on the verge of producing a super giant capable of competing globally [5][11]. - The combination of policy support, resource acquisition, and technological innovation is expected to drive the industry towards a more competitive and innovative future [10][11].

Industry Overview - Vaccines are essential biological products for preventing and controlling infectious diseases, representing a core defense in public health systems [1][5] - The Chinese vaccine industry is experiencing rapid growth, with the market size projected to increase from 306.22 billion yuan in 2015 to 1,762.19 billion yuan in 2024, and expected to exceed 300 billion yuan by 2031 [1][5] Industry Chain - The upstream of the vaccine industry includes raw material supply, such as microcarriers, human serum albumin, and packaging materials [3] - The midstream involves vaccine research and production, with key players including Sinopharm, Sinovac, CanSino, Zhifei, and Watson [3] - The downstream consists of vaccine distribution and consumption, reaching end consumers through health service centers and medical institutions [3] Current Industry Status - As of December 31, 2024, 47 companies in China have received vaccine batch approvals, totaling 543 million doses, with a decrease of 5.6% compared to 2023 [7] - The most approved vaccines in 2024 were influenza and rabies vaccines, each exceeding 80 million doses, accounting for 30% of total approvals [9] Market Competition - The Chinese vaccine market is characterized by a diverse competitive landscape, with local companies like Sinopharm and Zhifei rising against foreign giants like Merck and Pfizer [11] - Zhifei has achieved significant growth in international markets, with a 300% increase in exports of its WHO-precertified 23-valent pneumococcal polysaccharide vaccine [11] - Innovative companies like CanSino and Watson are making breakthroughs in mRNA and recombinant protein vaccines, enhancing their market presence [11][12] Future Trends - Technological innovation is driving the vaccine industry forward, with new platforms like mRNA and gene-engineered vaccines emerging [17] - The adult vaccine market is growing, with a 45% increase in HPV vaccine uptake in 2024, indicating a shift in public health awareness [18] - Chinese vaccine companies are expanding internationally, with over 2.5 billion doses of COVID-19 vaccines supplied abroad, focusing on markets in Africa and Southeast Asia [19]

Core Viewpoint - The company, Hualan Biological Engineering Co., Ltd., is revising its Articles of Association and related governance documents to comply with new regulations and improve corporate governance practices [1][2]. Summary by Sections Revision of Articles of Association - The company is amending its Articles of Association and related rules to align with the new Company Law and relevant regulations [1]. - Specific changes include the definition of the legal representative, responsibilities of the board, and shareholder rights [1][2]. Key Amendments - The legal representative will now be the Chairman of the Board, and the company must appoint a new legal representative within 30 days of any resignation [1]. - The company’s total share capital is confirmed to be 1,827,456,666 shares [2]. - The company will not provide financial assistance for acquiring its shares, except under specific conditions approved by the shareholders [2][3]. Shareholder Rights and Responsibilities - Shareholders have the right to request information, attend meetings, and propose resolutions [6][7]. - The company must ensure equal rights for shareholders holding the same class of shares [6][7]. - Shareholders holding more than 5% of shares must report any pledges of their shares [12][13]. Governance and Decision-Making - The company’s governance structure allows for shareholder meetings to decide on major issues such as capital increases, mergers, and financial audits [16][17]. - The company must obtain shareholder approval for external guarantees exceeding certain thresholds [16][17]. Legal Compliance - The company is required to comply with legal obligations regarding shareholder rights and corporate governance [12][14]. - Any resolutions made by the board or shareholders that violate laws can be challenged in court [8][9].

Group 1 - The core point of the announcement is the approval of the 2025 executive compensation plan for senior management at Hualan Biological Engineering Co., Ltd. [1][2] - The compensation plan includes a basic salary and performance-based salary, with the basic salary being fixed and paid monthly, while the performance salary is linked to the company's profit completion rate and assessment results [1][2] - The plan is applicable to senior management personnel, including the general manager, executive vice general manager, vice general managers, financial director, and board secretary, for the period from January 1, 2025, to December 31, 2025 [1][2] Group 2 - The compensation for senior management holding multiple positions will be calculated based on the highest position, avoiding duplicate payments [2] - The compensation is pre-tax income, with personal income tax withheld and paid by the company [2] - The compensation and assessment committee supervises the implementation of the annual performance assessment system, and actual payment amounts may vary [2] Group 3 - The compensation plan was reviewed and approved by the board's compensation and assessment committee, which deemed it reasonable and compliant with relevant laws and regulations, benefiting the company and all shareholders [2] - The plan aims to enhance the diligence and responsibility of senior management, improving the overall management level of the company and aligning with its long-term development goals [2]